Celyad Oncology SA
F:1C0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Celyad Oncology SA
F:1C0
|
BE |
|
G
|
Gia Tzoong Enterprise Co Ltd
TPEX:5355
|
TW |
|
Elevra Lithium Ltd
F:DML2
|
AU |
|
G
|
Go Metals Corp
XMUN:47G
|
CA |
|
B
|
Blackbird PLC
OTC:BBRDF
|
UK |
|
G
|
Graincorp Ltd
OTC:GRCLF
|
AU |
|
Ensysce Biosciences Inc
NASDAQ:ENSC
|
US |
|
Rapid7 Inc
LSE:0KTX
|
US |
|
P
|
Persol Holdings Co Ltd
F:59R
|
JP |
|
D
|
DaehanPharmaceutical
KOSDAQ:023910
|
KR |
|
A
|
Axon Partners Group SA
MAD:APG
|
ES |
|
Repsol SA
F:REP
|
ES |
|
Fiducian Group Ltd
ASX:FID
|
AU |
|
Clara Resources Australia Ltd
F:0H8A
|
AU |
|
H
|
Hasen-Immobilien AG
XMUN:ABHA
|
DE |
|
C
|
Chun Zu Machinery Industry Co Ltd
TPEX:4544
|
TW |
|
O
|
Orosur Mining Inc
F:UR2
|
CA |
|
M
|
Movado Group Inc
F:MV4
|
US |
|
Lighthouse Properties PLC
F:87O
|
MT |
|
F
|
Falco Resources Ltd
SWB:8FP
|
CA |
|
C
|
Credit Corp Group Ltd
OTC:CCGFF
|
AU |
Bankruptcy Probability
Celyad Oncology SA's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Celyad Oncology SA Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BE |
|
Celyad Oncology SA
XBRU:CYAD
|
9.8m EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
AbbVie Inc
NYSE:ABBV
|
471.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
217.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences, Inc
NASDAQ:GILD
|
179B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
127.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
76.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Moderna Inc
NASDAQ:MRNA
|
74.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.2B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
52.4B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Natera Inc
NASDAQ:NTRA
|
57.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
42.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Celyad Oncology SA's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Celyad Oncology SA has no debt.
You can find a full breakdown on its Balance Sheet.